Vaccines

Analysis of mRNA Therapeutics and Vaccines

February 03, 2022

Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Global Vaccine Access Challenges FDA and Industry

February 02, 2022

The global nature of the COVID-19 pandemic emphasizes the critical importance of expanded vaccination.

Cytiva Provides Arranta Bio with Single-Use Manufacturing Platform for mRNA Products

February 01, 2022

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

COVID-19 Vaccination Offers Protection from Hospitalization due to Omicron Variant, According to Report

January 21, 2022

A report by international regulators reviews the effectiveness of current COVID-19 vaccines against the omicron variant.

Sustainable Shippers for Ultra-Cold Conditions

January 17, 2022

Protective external packaging ensures COVID-19 vaccines arrive safely.

Pfizer and Acuitas Therapeutics Collaborate on Lipid Nanoparticle Delivery System

January 11, 2022

The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.

Clinical Trial on Intranasal Coronavirus Vaccine Set to Start

January 07, 2022

Intravacc is partnering with Leiden University Medical Center for the development and evaluation of a new intranasal coronavirus vaccine candidate in a clinical Phase I/II study.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

Sanofi to Acquire Origimm Biotechnology for Vaccine-based Acne Treatment

December 09, 2021

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

November 29, 2021

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.